Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate

NCT02349451 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02349451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02349451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
April 28, 2015
Completion date
July 4, 2016
Enrollment
240 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis